Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib, Vorinostat, and Bortezomib in AML
NCT01534260Phase 2Completed
- Start
- Feb 2012
- Primary completion
- Aug 2016
- Modality
- Modified Peptides, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib, vorinostat, bortezomib in acute myeloid leukemia (AML). Started Feb 2012; status: completed.
02
Drugs
sorafenibvorinostatbortezomib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01534260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01534260.